Compounds > bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii)
Page last updated: 2024-09-03

bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) and Mesothelioma

bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) has been researched along with Mesothelioma in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's2 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davidson, R; Feig, B; Hu, W; Khokhar, AR; Kumagai, S; Lee, SJ; Maclean, DS; Mansfield, P; Siddik, ZH; Verschraegen, CF1
Feng, L; Hong, WK; Khokhar, AR; Lopez-Berestein, G; Lu, C; Perez-Soler, R; Piperdi, B; Ro, JY; Shin, DM; Shin, HJ; Smythe, WR; Swisher, SG; Truong, M; Walsh, GL; Yalamanchili, A1
Hong, WK; Huber, M; Khokhar, AR; Lee, SJ; Murphy, WK; Perez-Soler, R; Shin, DM; Siddik, ZH1

Trials

3 trial(s) available for bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) and Mesothelioma

ArticleYear
Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.
    Journal of cancer research and clinical oncology, 2003, Volume: 129, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Area Under Curve; Ascites; Carcinoma, Signet Ring Cell; Colorectal Neoplasms; Endometrial Stromal Tumors; Female; Humans; Injections, Intraperitoneal; Liposomes; Male; Mesothelioma; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Peritoneum; Radionuclide Imaging; Technetium; Tissue Distribution

2003
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-20, Volume: 23, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Biopsy, Needle; Chemotherapy, Cancer, Regional Perfusion; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Female; Follow-Up Studies; Humans; Immunohistochemistry; Liposomes; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Pleural Neoplasms; Probability; Risk Assessment; Survival Rate; Thoracoscopy; Treatment Outcome

2005
Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Drug Carriers; Female; Humans; Liposomes; Lung Neoplasms; Male; Mesothelioma; Metabolic Clearance Rate; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Pleura; Pleural Effusion, Malignant; Pleural Neoplasms; Rats

1997